Related Experiment Videos
[Studies on melatonin gelatin microspheres for intranasal administration]
1Department of Pharmaceutics, Shenyang Pharmaceutic University, Shenyang 110015, China.
Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|May 25, 2001
Summary
Melatonin gelatin microspheres (MT-GMS) offer enhanced intranasal delivery. This formulation significantly boosts melatonin bioavailability in rabbits compared to standard solutions.
Area of Science:
- Pharmacology
- Materials Science
- Biomedical Engineering
Context:
- Melatonin (MT) has low oral bioavailability, limiting its therapeutic use.
- Intranasal drug delivery offers a potential alternative route for enhanced systemic absorption.
- Developing effective intranasal formulations is crucial for improving drug efficacy.
Purpose:
- To prepare and characterize melatonin gelatin microspheres (MT-GMS) for intranasal administration.
- To optimize the preparation of MT-GMS using emulsifying-cross linking techniques and orthogonal tests.
- To evaluate the in vivo residence time and bioavailability of MT-GMS in a rabbit model.
Summary:
- Melatonin gelatin microspheres (MT-GMS) were successfully prepared with a mean diameter of 50.2 microns and drug content of 13.48%.
- In vitro studies demonstrated a sustained release profile for MT-GMS.
- Gamma scintigraphy revealed prolonged residence time of GMS in the rabbit nasal cavity compared to gelatin solution, with intranasal MT-GMS achieving 87.47% bioavailability versus 69.72% for MT solution.
Impact:
- MT-GMS formulation meets the requirements for intranasal administration.
- The developed microspheres significantly enhance the bioavailability of melatonin.
- This study provides a promising strategy for improving melatonin's therapeutic potential through optimized intranasal delivery.